StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance NASDAQ:CLLS opened at $2.51 on Friday. The company’s 50-day moving average price is $2.62 and its 200-day moving average price is $2.65. […]